The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.

J&J failed to convince BBB National Program’s appeals panel a 2008 NAD decision supporting its “#1 dermatologist recommended” claim for Neutrogena should preclude another review. Panel says market has changed in 12 years since review of Unilever challenge and L’Oreal could make its own challenge.

A combined $447.2m are raised through a Hong Kong initial public offering (IPO) and venture capital and private equity deals.

Manufacturers should expect that remote audits of suppliers may take longer than onsite ones until they get more familiar with these audits; it is also important to abide by data confidentiality rules and take frequent breaks when conducting these audits, says Rx-360 CEO.